Innovating and Access: Alternative R&D Models

K M Gopakumar

TWN
Problem with the Patent Lead R&D Model

• Compromises access
• Market failure
Problem of 90/10

• Little R&D funding to meet the health needs of developing countries
• MSF Study : Only 1% of the 1,400 new medicines created in the last 25 years were developed for the treatment of tropical disease. (1975-2025)
• DNDI MSF Study : 2000-11 only 4 NCEs out of approved for Neglected Diseases i.e. 1%
Unmet Needs

• New medicines/diagnostics/devices
• FDCs
• Modified dosage
• Adaptation to local needs
R&D Financing for Neglected Diseases

- Les involvement of pharmaceutical TNCS
- Project Development Partnerships
- Public Sector and Foundation Funding
Guiding Principles for R&D

• Innovation and access based on principle of de linkage

• R&D Models to achieve delinkage
  – Grant
  – Prizes
  – Advance marketing commitment
  – Milestone payment
  – Open innovation
WHO Process

• GSOPA

• CEWG Report and Recommendation
  • R&D Treaty for coordination, prioritization and Financing

• UN High level panel on A2M
  – R&D Treaty
WHO State of Play

- CEIPI
- R&D Blue Print
- Demonstration project
Scope for Activism

• International
• National